Market revenue in 2024 | USD 311.6 million |
Market revenue in 2030 | USD 749.3 million |
Growth rate | 15.9% (CAGR from 2025 to 2030) |
Largest segment | Sequence analysis platforms |
Fastest growing segment | Sequence Analysis Platforms |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Sequence Analysis Platforms, Molecular Modelling, Docking, Clinical Trial Data Management |
Key market players worldwide | Certara Inc Ordinary Shares, Boehringer Ingelheim, Infosys Ltd ADR, Charles River Laboratories International Inc, Eli Lilly and Co, Novo Nordisk A/S ADR, Oracle Corp, Accenture PLC Class A, Agilent Technologies Inc, Illumina Inc, Eurofins Scientific SE, Jubilant Biosys, Selvita, ChemAxon, Albany Molecular Research |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug discovery informatics market will help companies and investors design strategic landscapes.
Sequence analysis platforms was the largest segment with a revenue share of 42.14% in 2024. Horizon Databook has segmented the China drug discovery informatics market based on sequence analysis platforms, molecular modelling, docking, clinical trial data management covering the revenue growth of each sub-segment from 2018 to 2030.
China is expected to register lucrative growth over the forecast period with respect to revenue in this market. Factors that are expected to attribute towards high growth of this region include government initiatives for introduction of novel drugs in the market with the utilization of computational tools and platforms.
Drug discovery is anticipated to witness lucrative growth in China thus influencing informatics growth. Many international companies have established their R&D centres in Beijing, Shanghai, Wuhan, Suzhou, and other parts of the country and are conducting multi-centre clinical trials in China.
This is leading to generation of enormous data consequently raising demand for data management solutions. Furthermore, Chinese domestic companies are catching up by building and investing in their scientific research programs and teams.
Horizon Databook provides a detailed overview of country-level data and insights on the China drug discovery informatics market , including forecasts for subscribers. This country databook contains high-level insights into China drug discovery informatics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account